Skip to main content
Premium Trial:

Request an Annual Quote

Fisher, Evotec

Premium

Fisher's Q3 Revenues Grow 13 Percent as Profit More Than Doubles

Fisher Scientific last week reported a 13-percent increase in revenues, and more than doubled its net income for the three months ended Sept. 30.

Fisher's revenues for the third quarter rose to $1.4 billion from $1.26 billion in the same period a year ago.

Net income also surged to $94 million, or $0.77 per basic share, from $36 milllion, or $0.36 per basic share in the year-ago period.

Fisher Scientific had approximately $189.2 million in cash and cash investments as of Sept. 30.

The company did not report R&D expenditures for the quarter.

In September, Fisher acquired HCS shop Cellomics for $49 million (see CBA News, 9/12/2005).


Evotec Tech Sees Losses Increase by
43 Percent amid 54-Percent Revenue Growth

Evotec Technologies, the technology division of Evotec OAI, last week reported a 54-percent growth in third-party revenue, but saw its net losses increase by 43 percent for the third quarter ended Sept. 30.

Evotec Tech's third-party revenues for Q3 rose to €3.96 million ($4.64 million), from €2.58 million in the year-ago period.

The division posted a net loss of €1.95 million in Q3, compared to €1.37 million in Q3 2004. The Tech division spent €1.5 million on R&D in Q3, on par with the amount it spent in the same quarter last year.

Evotec Tech is a subsidiary of German drug-discovery firm Evotec OAI, and counts the Opera confocal plate reader and EVOScreen integrated high-throughput screening platform among its offerings.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.